Neuroscience Today—April 8, 2026

This week’s Neuroscience update highlights regulatory progress, positive clinical data, pipeline expansion, conference catalysts, and reimbursement gains across rare and broader neurological conditions.

In Today’s Newsletter

Dive deeper

🧠 Evommune expands EVO756 migraine narrative [1] [US • 06 Apr 2026]

https://www.biospace.com/press-releases/evommune-to-host-kol-webinar-on-april-13-2026-highlighting-the-potential-of-mrgprx2-inhibition-in-migraine
Context: Evommune (NYSE: EVMN) said EVO756, an MRGPRX2 antagonist, is being positioned for a third indication, migraine prophylaxis.
Key point: The company announced a KOL webinar for 13 Apr 2026 and said a Phase 2b migraine study is planned to start in 3Q26.
Implication: Signals pipeline investment and modality expansion.

💊 Rapport Therapeutics tees up RAP-219 follow-up at AAN [2] [US • 01 Apr 2026]

https://www.globenewswire.com/fr/news-release/2026/04/01/3266457/0/en/Rapport-Therapeutics-to-Present-New-Phase-2-Treatment-Follow-Up-Data-for-RAP-219-in-Focal-Onset-Seizures-at-the-2026-American-Academy-of-Neurology-Annual-Meeting.html
Context: Rapport Therapeutics will present Phase 2a data for RAP-219 in focal onset seizures, including an 8-week follow-up period, at AAN 2026 in Chicago.
Key point: The company said the podium presentation will cover efficacy and tolerability, with RNS long episodes and clinical seizures named in the session title.
Implication: May influence prescriber choice and payer reviews pending full data.

👁️ Oculis wins EMA PRIME for Privosegtor in optic neuritis [3] [EU • 31 Mar 2026]

https://investors.oculis.com/news-releases/news-release-details/oculis-announces-european-medicines-agency-prime-designation
Context: Oculis said Privosegtor already has FDA Breakthrough Therapy designation and orphan status from both EMA and FDA for optic neuritis.
Key point: EMA granted PRIME designation for Privosegtor in optic neuritis, supported by Phase 2 ACUITY results and ongoing PIONEER registrational development.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Praxis posts positive elsunersen topline in SCN2A DEE [4] [US • 06 Apr 2026]

https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-results-embrave
Context: EMBRAVE Part A was a randomized, placebo-controlled Phase 1/2 trial in nine pediatric patients with early-seizure onset SCN2A developmental and epileptic encephalopathy.
Key point: Praxis reported 77% placebo-adjusted seizure reduction from baseline, 71% of treated patients with greater than 50% seizure reduction by period 6, and no drug-related serious adverse events.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Plus Therapeutics expands CNSide payer access with Highmark [5] [US • 02 Apr 2026]

https://www.manilatimes.net/2026/04/02/tmt-newswire/globenewswire/plus-therapeutics-secures-highmark-coverage-for-cnside-csf-assay-expanding-reimbursement-to-75-million-covered-lives/2313336
Context: CNSide Diagnostics, a Plus Therapeutics subsidiary, markets the CNSide cerebrospinal fluid tumor cell enumeration assay for metastatic CNS cancers and leptomeningeal metastases management.
Key point: Highmark coverage became effective 01 Apr 2026, increasing reimbursed lives from about 67 million to 75 million.
Implication: May expand screening, initiation, and follow-up at scale.

🦴 FDA clears higher-dose nusinersen for SMA [6] [US • 04 Apr 2026]

https://www.pharmacytimes.com/view/fda-approves-higher-dose-regimen-of-nusinersen-for-spinal-muscular-atrophy
Context: Pharmacy Times said the decision was supported by Phase 3 DEVOTE data and described safety as consistent with prior nusinersen experience.
Key point: FDA approved a higher-dose nusinersen regimen for spinal muscular atrophy, with the article citing improved cerebrospinal fluid exposure and favorable motor outcomes.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it Matters

Neurology pipelines continue to diversify, spanning migraine, epilepsy, optic neuritis, SMA, and CNS oncology diagnostics [1][2][3][4][5][6].
Regulatory momentum remains a major value driver, especially for Privosegtor in optic neuritis and nusinersen in SMA [3][6].
Precision and rare-disease programs are still generating investable catalysts through conference data, toplines, and label updates [2][4][6].
Commercial traction is not limited to therapeutics, CNSide shows that reimbursement expansion can be a major adoption lever in neuro-oncology diagnostics [5].
Several readouts remain interim or source-described, so clinical interpretation still depends on fuller datasets and peer-reviewed disclosure [2][4][6].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Neuroscience archive on our research hub page.

FAQ

What did Evommune say about EVO756 in migraine?

Evommune said EVO756, an MRGPRX2 antagonist, is being advanced into migraine prophylaxis as a third indication. The company also said a Phase 2b study is expected to begin in 3Q26. [1]

What is new for Rapport Therapeutics’ RAP-219 program?

Rapport said it will present new Phase 2a follow-up data for RAP-219 in focal onset seizures at the 2026 AAN Annual Meeting. The announcement is about an upcoming presentation, not a full data release. [2]

Why is EMA PRIME for Privosegtor important?

Oculis said PRIME provides early and proactive EMA support for medicines that may address significant unmet need. For Privosegtor, this adds to prior FDA Breakthrough Therapy designation in optic neuritis. [3]

How strong were the EMBRAVE Part A topline data for elsunersen?

Praxis reported placebo-adjusted seizure reduction of 77% and said no treatment-emergent or serious adverse events were related to study drug. The dataset is small, nine patients, and fuller details are still pending. [4]

What changed for CNSide reimbursement?

Plus Therapeutics said Highmark coverage for the CNSide CSF assay took effect on 01 Apr 2026. That raised covered lives to about 75 million and could reduce reimbursement friction for ordering physicians. [5]

What does the higher-dose nusinersen approval add in SMA?

The article says FDA approved a higher-dose maintenance option intended to increase CSF exposure. It cites DEVOTE findings and notes safety remained consistent with prior nusinersen experience. [6]

Entities / Keywords

Evommune, EVO756, MRGPRX2 antagonist, migraine prophylaxis, Rapport Therapeutics, RAP-219, focal onset seizures, AAN 2026, Oculis, Privosegtor, optic neuritis, EMA PRIME, ACUITY, PIONEER, Praxis Precision Medicines, elsunersen, EMBRAVE, SCN2A developmental and epileptic encephalopathy, Plus Therapeutics, CNSide Diagnostics, CNSide CSF assay, leptomeningeal metastases, Highmark, Biogen, nusinersen, Spinraza, spinal muscular atrophy, DEVOTE